Open Access

Erratum to: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity

  • Benny Sørensen1Email author,
  • Donat R Spahn2,
  • Petra Innerhofer3,
  • Michael Spannagl4 and
  • Rolf Rossaint5
Critical Care201115:409

https://doi.org/10.1186/cc10094

Published: 18 March 2011

The original article was published in Critical Care 2011 15:201

Correction

After publication of our article [1] we noted that in Table 1 for Prothrombinex-VF 'Antithrombin and heparin added' should have been included under the 'Additional information' column. A copy of the table with the correct information can be found overleaf.
Table 1

Composition of PCCs in the World Federation of Hemophilia register of clotting factor concentrates

  

International units relative to factor IX

  

Brand name

Manufacturer

Factor II

Factor VII

Factor IX

Factor X

Viral inactivation

Additional information

Bebulin VH

Baxter BioScience, Austria

120

(13)

100

100

Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar

Heparin added

Beriplex P/N

CSL Behring, Germany

128

68

100

152

Pasteurisation at 60°C for 10 hours, and nanofiltration

Protein C; antithrombin, heparin and albumin added

Cofact

Sanquin, the Netherlands

56-140

28-80

100

56-140

Solvent/detergent and 15 nm nanofiltration

Antithrombin added

KASKADIL

LFB, France

148

40

100

160

Solvent/detergent

Heparin added

Octaplex

Octapharma, Austria and France

44-152

36-96

100

50

Solvent/detergent and nanofiltration

Heparin added; low activated factor VII content

Profilnine SD

Grifols, USA

148

(11)

100

64

Solvent/detergent

-

Prothrombinex VF

CSL Bioplasma, Australia

100

(-)

100

100

Dry heat, 80°C for 72 hours and nanofiltration

Antithrombin and heparin added

Prothromplex T

Baxter BioScience, Austria

100

85

100

100

Vapour heat, 60°C for 10 hours at 190 mbar, then 80°C for 1 hour at 375 mbar

Antithrombin and heparin added

UMAN Complex D.I.

Kedrion, Italy

100

(-)

100

80

Solvent/detergent and dry heat, 100°C for 30 minutes

Antithrombin and heparin added

Composition of prothrombin complex concentrates (PCCs) listed in the World Federation of Hemophilia register of clotting factor concentrates [54], excluding concentrates for national markets only or for which the concentrations of factors relative to factor IX were not available from the relevant product information sheets. Factor VII presented in parentheses for three-factor PCCs.

Notes

Authors’ Affiliations

(1)
Haemostasis Research Unit, Centre for Haemostasis and Thrombosis, Department of Haematology and Oncology, Guy's and St Thomas' Hospital & NHS Trust Foundation, King's College London School of Medicine
(2)
Institute of Anesthesiology, University Hospital Zurich
(3)
Department of Anaesthesiology and Critical Care Medicine, Innsbruck Medical University
(4)
Working Group on Perioperative Hemostasis, Department of Anaesthesiology, University Hospital of Munich
(5)
Department of Anaesthesiology, University Hospital Aachen, RWTH Aachen University

References

  1. Sørensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R: Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. Crit Care. 2011, 15: 201-10.1186/cc9311.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© BioMed Central Ltd 2011

Advertisement